No Picture
News

Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study

– PRA023 is a TL1A antibody targeting both inflammation and fibrosis in patients with ulcerative colitis and Crohn’s disease — PRA023 is being developed to be used in combination with a companion diagnostic to identify responders in novel precision me… […]

No Picture
News

Alume Receives SBIR Phase II Grant from the NIH to Support Clinical Trial of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery

LA JOLLA, Calif., Dec. 15, 2020 /PRNewswire/ — Alume Biosciences, Inc. (Alume) announced today that it has been awarded a $2.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stro… […]

No Picture
News

Alume Receives SBIR Phase II Grant from the NIH to Support Clinical Trial of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery

LA JOLLA, Calif., Dec. 15, 2020 /PRNewswire/ — Alume Biosciences, Inc. (Alume) announced today that it has been awarded a $2.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stro… […]

No Picture
News

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

– 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU- Multiple Global Phase 2/3 Trials to Begin Early 2021

SAN DIEGO, Dec. 10, 2020 /PRNewswire/ — Ambrx Inc., a clini… […]

No Picture
News

Biocept’s Target Selector(TM) Liquid Biopsy Demonstrated High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

Using Target Selector(TM) to detect HER2 alterations assists physicians in reassessing therapy options over the course of treating patients with metastatic breast cancer

SAN DIEGO, Dec. 10, 2020 /PRNewswire/ — Biocept, Inc. (Nasdaq: BIOC), a leading… […]

No Picture
News

Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study

– Tolperisone was comparable to placebo on driving performance; cyclobenzaprine, market leading skeletal muscle relaxant, was significantly worse at all time points- Tolperisone similar to placebo on three measures of sleepiness whereas cyclobenzaprine… […]

No Picture
News

Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study

– Tolperisone was comparable to placebo on driving performance; cyclobenzaprine, market leading skeletal muscle relaxant, was significantly worse at all time points- Tolperisone similar to placebo on three measures of sleepiness whereas cyclobenzaprine… […]

No Picture
News

Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial

– Evaluating 2 mg etrasimod in study participants with moderately to severely active ulcerative colitis (UC)- Topline data from ELEVATE UC 12 and UC 52 trials on track for Q1 2022- Due to the high number of participants currently in screening queue, sc… […]